USPTO serial 86960150
BTG
Reviewed by CopyMark Law Group
Reg. 5577939Status 710
- Filing date
- Status date
- Registration date
- Oct 9, 2018
- Examiner
- STRINGER, DANIEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with BTG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
London, GB
PROTHERICS MEDICINES DEVELOPMENT LIMITED
London, GB
Other trademarks owned by PROTHERICS MEDICINES DEVELOPMENT LIMITED
London, GB
London, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan A. Hyman
Jonathan A. Hyman Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medicinal and veterinary preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure; sanitary preparations for medical purposes; vaccines; pharmaceutical and medicinal preparations and substances, namely, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances, and sepsis; diagnostic reagents and substances, all for in vivo medical use; antibodies, and therapeutic antibodies for use as anti-lymphocytic agents for medical use; pharmaceutical preparations in the form of foams or for use in producing foams, for sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, intracranial hemorrhages, cerebral hemorrhages, hematomas, and as antidotes; pharmaceutical preparations for the treatment of cancer; pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of multiple neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of immune disorders namely, type 1 diabetes, psoriasis, coeliac disease and rheumatoid arthritis; pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; pharmaceutical preparations for the treatment of sepsis; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical prepraations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical or veterinary therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity, and for use in the treatment of pre-eclampsia; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity and for use in the treatment of pre-eclampsia; transarterial chemoembolization pharmaceutical preparations, vaccines and sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; beads, including microscopic radioactive beads, for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumours; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and treatment of autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents | SECTION 8 - CANCELLED | — |
| 009 | Computer hardware for medical imaging apparatus; computer firmware for controlling medical devices; computer firmware for controlling and managing patient medical information; computer hardware; computer peripherals; computer software and computer programs for medical monitoring, medical testing and patient evaluating programs; computer programs for controlling and managing patient medical information; computer software for use in medical devices, namely, software for the operation of medical devices and for analyzing the results of testing completed through medical devices; computer software for use in ultrasound devices, namely, software for the operation of ultrasound devices and for analyzing ultrasound images; computer software for use in the medical and pharmaceutical fields for the diagnosis, treatment, and management of health conditions and illnesses; computer software for the diagnosis, assessment, treatment, management, and aftercare of conditions in the fields of sclerotherapy, phlebology, angiology, proctology and interventional oncology and emphysema; computer software for the diagnosis, assessment, treatment, management, and aftercare of tumors; computer software and computer programmes providing information to medical professionals and patients, namely, computer software for the diagnosis, assessment, treatment, management, and aftercare of varicose veins, arterio-venous malformations, oesophageal varices, and hydroceles; computer software for the diagnosis, assessment, treatment, management and aftercare of emphysema; computer software for controlling and managing patient medical information; computer programs for use in the field of health care for the collection, maintenance and management of data for patient records, clinical diagnosis and assessment, patient treatment, goals management, outcome analysis, scheduling, health care facilities management, materials management, resources utilization, billing and accounting, and the review of health care facilities, services and clinical records; computer software for use by health care providers to analyse the outcomes of medical procedures and information relating to patient care; computer software for use in database management; computer databasing software for clinical use, clinical governance and clinical audit for collecting and analysing information relating to patient demographics, procedures and outcomes; computer operating software and computer displays for use in relation to medical purposes; computer hardware, computer operating software and computer operating programs in the field of ultrasound technology; apparatus for generating and transmitting ultrasound; electric and electronic control systems for controlling medical apparatus and instruments; electric and electronic control systems for controlling apparatus for generating and transmitting ultrasound; data processing apparatus and computers for controlling medical apparatus and instruments; data processing apparatus and computers for controlling apparatus for generating and transmitting ultrasound; computer software for controlling medical apparatus and instruments; computer software for controlling apparatus for generating and transmitting ultrasound; stands for computer hardware; medical software for processing and displaying images on ultrasound medical imaging apparatus; medical imaging software that records, monitors and analyses data using an ultrasound imaging probe; medical workstation comprised of computer hardware and software for gathering and transmitting patient image data for use during surgical procedures; software for processing digital images of the anatomy for diagnosis and treatment; software for medical imaging; computer software for ultrasound imaging and scanning; Downloadable publications in the nature of electronic questionnaires in the field of healthcare, medicine, medical treatment and patient care; Downloadable publications in the nature of electronic patient reported outcome questionnaires in the fields of healthcare, medicine, medical treatment and patient care, patient reported outcomes, electronic patient reported outcome questionnaires and electronic patient reported outcome questionnaires for use with a telecommunications device; downloadable publications in electronic form, namely, journals, magazines, periodicals, articles and books in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, patient care, medical diseases, disorders and related treatments; downloadable electronic publications, namely, journals, magazines, periodicals, articles and books provided on-line from databases or the internet in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, patient care, medical diseases, disorders and related treatments; optical viewing and recording apparatus for viewing and recording sound, images or data; spectrophotometers; replacement parts and fittings for all the aforesaid goods | SECTION 8 - CANCELLED | — |
| 010 | Surgical, medical, dental and veterinary apparatus and instruments, namely, cryoablation needles, medical syringes, electrically powered tissue ablation devices, surgical and medical apparatus and instruments for administering pharmaceutical foams, surgical and medical apparatus and instruments for treatment of varicose veins, arterio-venous malformations, oesophageal varices and hydroceles, devices for intravenous administration of pharmaceutical foam, and diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose, surgical and medical apparatus and instruments for use in minimally invasive cryoablation procedures; artificial limbs; orthopaedic articles, namely, implants made of artificial materials; medical syringes, medical cannula needles, medical tubing; surgical and medical apparatus for administering foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; surgical and medical devices for assessing the physical characteristics of such foams, namely, devices for intravenous administration of foam, medical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes, and devices for monitoring the position and effect of foam in the human body; medical diagnostic devices for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; haemofiltration devices for medical use; drug delivery embolisation apparatus, instruments and systems; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolisation; drug delivery embolisation systems; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; Implantable radioactive therapy beads, namely, microscopic glass beads containing radioactive material and administered surgically for treatment of cancerous tumours; implantable radioactive therapy beads, namely, radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; medical devices which use ultrasound to enhance drug delivery and/or medically activate drugs; catheters for delivery of drugs or fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; syringes for administering foams for use in sclerotherapy, phlebology, angiology or proctology; surgical and medical apparatus for administering foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of foam in the human body; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; medical devices for use in pulmonary and thoracic surgery and procedures; lung volume reduction devices; artificial surgical implants for use in interventional pulmonology; surgical implants comprising artificial surgical implants for restoring, maintaining and improving patient breathing, and artificial surgical implants for restoring, maintaining and improving lung function; medical equipment for diagnostic purposes, namely, ultrasound imaging systems comprising ultrasound scanners and ultrasound imaging devices; electrically operated diagnostic testing apparatus and instruments for medical use, namely, electrically operated diagnostic testing apparatus and instruments for use in testing for symptoms, the presence of diseases or disorders or specific side effects in the fields of sclerotheraphy, phlebology, angiology proctology, interventional oncology, tumors, basal cell carcinoma, emphysema, varicose veins, arterio-venous malformations, oesophageal varices, hydroceles and skin complaints including psoriasis and eczema; ultrasonic medical diagnostic apparatus; replacement parts and fittings for all of the aforesaid goods | SECTION 8 - CANCELLED | — |
| 041 | Education, namely, developing, arranging and conducting educational conferences, seminars, workshops and programs and providing courses of instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments, pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrhages, and hematoma, cryoablation and distribution of course materials in connection therewith; Educational services, namely, conducting live and online seminars, classes, workshops, conferences, lectures, panel discussions and training in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments, pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrhages, and hematoma, cryoablation and distribution of course materials in connection therewith; Education services, namely, conducting online and telephonic instruction and courses in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments, pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrhages, and hematoma, cryoablation and distribution of course materials in connection therewith; provision of educational content, namely, providing on-line instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments, and pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma, cryoablation and distribution of course materials in connection therewith; providing educational training in relation to pulmonary and thoracic surgery and procedures and distribution of course materials in connection therewith; educational services, namely, development of multimedia educational content for use with mobile devices and computers, namely, a series of health-related questions for response from the user that result in a report that provides health-related information in the form of recommended educational resources and treatment information in relation to pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrhages, and hematoma and cryoablation; providing computer, electronic and on-line databases in the field of education concerning healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care, medical diseases, disorders and related treatments, and pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrhages, and hematoma, and cryoablation; provision of educational training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; provision of educational training in the fields of health and medicine by means of a hotline services; arranging, and conducting educational conferences and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Providing on-line non-downloadable publications in the nature of teaching guides, instructional materials, brochures and pamphlets in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; conducting educational seminars in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials therewith; information and advice in the field of educational training provided online from a computer database or the internet, all relating to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Non-downloadable electronic publications in the nature of teaching guides, instructional materials, brochures in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine, medical diseases, disorders and related treatments, and pulmonary and thoracic surgery and procedures, and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and Intracranial Hemorrhages, cerebral hemorrages, and hematoma and cryoablation; providing educational electronic online databases featuring information about medical education in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; providing online, non-downloadable electronic publications in the nature of electronic questionnaires in the field of healthcare, medicine, medical treatment and patient care; providing online, non-downloadable electronic patient reported outcome questionnaires in the fields of healthcare, medicine, medical treatment and patient care, patient reported outcomes, electronic patient reported outcome questionnaires and electronic patient reported outcome questionnaires for use with a telecommunications device | SECTION 8 - CANCELLED | — |
| 042 | Providing on-line, non-downloadable educational software featuring instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BTG International Limited
- Other trademarks owned by PROTHERICS MEDICINES DEVELOPMENT LIMITED
- Other trademarks owned by BTG International Limited
- Other trademarks owned by BTG International Limited
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named BTG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 25, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Oct 9, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 13, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 13, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 16, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 16, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 16, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 12, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 12, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 12, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 12, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 12, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 12, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 30, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 30, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 30, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 30, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 14, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 29, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 29, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 29, 2020 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Aug 29, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 29, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 29, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 9, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 18, 2018 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 18, 2018 | ISPO | WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST | — |
| Jun 18, 2018 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 12, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 12, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 24, 2018 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| May 23, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 9, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 9, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 9, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 9, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 9, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 13, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 6, 2017 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Aug 15, 2017 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jul 31, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 18, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 17, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 17, 2017 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 1, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 1, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 1, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 25, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 25, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 23, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 23, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 26, 2016 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Apr 25, 2016 | ALIE | ASSIGNED TO LIE | — |
| Apr 7, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 6, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 5, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 4, 2016 | NWAP | NEW APPLICATION ENTERED | — |